Novo Nordisk A/S ADR (NVO)

$132.23 0.69 (0.53%)

12:21 EDT NVO Stock Quote Delayed 30 Minutes

3 ‘Strong Buy’ Stocks You Should Be Loading Up On Now

By Rich Duprey, InvestorPlace Contributor Aug 7, 2023

There are plenty of strong buy stocks that offer growth at a good price, even if their stocks have generated significant gains this year

7 A-Rated Stocks for Your August Buy List

3 Biotech Stocks to Buy Before Drug Trials End

3 Long-Term Stocks You Better Be Buying on Each and Every Dip

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 1.44M

Day's Range $131.85 - $133.18

52-Week Range $77.96 - $148.15

Dividend & Yield $1.77 (1.34%)

NVO Stock Predictions, Articles, and Novo Nordisk A/S ADR News

3 Biotech Stocks You Better Be Buying on Each and Every Dip

By Tyrik Torres, InvestorPlace Contributor Jul 27, 2023

Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.

7 ‘Monster’ Stocks to Buy Right Now

By Alex Sirois, InvestorPlace Contributor Jul 26, 2023

These best-performing stocks are simply worth buying due to scale and scope along with strong fundamentals.

3 Healthcare Stocks to Buy as the Market Gets Defensive

By Josh Enomoto, InvestorPlace Contributor Jul 18, 2023

With upcoming monetary policy likely to dominate discussions, these healthcare stocks for defensive investing should be buys.

3 Biotech Stocks That AI is Loving in July

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor Jul 12, 2023

As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.

DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership

By William White, InvestorPlace Writer Jul 11, 2023

Ginkgo Bioworks (DNA) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk.

3 Biotech Stocks With Blockbuster Potential

By Josh Enomoto, InvestorPlace Contributor May 24, 2023

Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.

7 Top Growth Stocks to Buy for the Next Decade

By Alex Sirois, InvestorPlace Contributor Apr 18, 2023

These Growth Stocks to Buy Don't Require a 10-year Horizon But Should be More Valuable Then

7 Healthcare Stocks That Will Be Big Winners in 2023

By Alex Sirois, InvestorPlace Contributor Jan 31, 2023

Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.

3 Global Stocks to Buy to Get Around America’s Slowdown

By Will Ashworth, InvestorPlace Contributor Jan 30, 2023

If you’re looking to put some of your cash to work in 2023, these three global stocks to buy could be better options than U.S. stocks.

7 Hot Stocks to Book Profits In Before 2023

By Josh Enomoto, InvestorPlace Contributor Dec 19, 2022

With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.

Our 7 Top Biotech Stock Picks for 2023

By Josh Enomoto, InvestorPlace Contributor Dec 9, 2022

Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.

Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News

By David Moadel, InvestorPlace Contributor Sep 1, 2022

There's a major pharmaceutical market deal afoot -- and it's worth over $1 billion -- so FMTX stock is heading higher on the news.

3 Stocks to Buy Before the Housing Market Crashes

By Alex Sirois, InvestorPlace Contributor Aug 26, 2022

Economists' expectations of a housing market crash are rising, making these potentially stocks stronger choices in the aftermath.

7 Long-Term Stocks to Buy Before the Bull Market Returns

By Muslim Farooque, InvestorPlace Contributor Aug 7, 2022

For massive future returns, consider taking a position in these long-term stocks to buy before the bull market returns.

ESG Investing: 7 Profitable Stock Picks for the Socially Responsible

By Tezcan Gecgil, InvestorPlace Contributor Jun 24, 2022

ESG investing has not been immune to declines in the current bear market

The 7 Best Long-Term Stocks to Buy and Hold Until 2032

By Ian Bezek, InvestorPlace Contributor May 26, 2022

Markets are shaky right now. But these seven best long-term stocks to buy and hold should work in just about any economic environment.

7 Pharmaceutical Stocks Working on Their Next Blockbuster

By Alex Sirois, InvestorPlace Contributor Mar 12, 2021

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs. These 7 are close.

7 Safe Stocks to Buy for Solid Returns in Tumultuous Times

By Ian Bezek, InvestorPlace Contributor Jan 28, 2021

While stocks keep going up and up, more risks are mounting under the surface. As such, you should be looking at safe stocks to buy now.

7 Cheap Stocks to Buy for 2021 That Deserve Recognition

By Alex Sirois, InvestorPlace Contributor Dec 3, 2020

These 7 cheap stocks span industry and have a great chance to appreciate in price next year. Click here for the metrics and reasoning.

Hold Novo Nordisk Shares for Consistent International Growth

By Louis Navellier and the InvestorPlace Research Staff Sep 30, 2020

The company's value chain may have been shaken by Covid-19 but it wasn't broken, so Novo Nordisk stock holders should stay invested.

Novo Nordisk A/S ADR (NVO)

3 ‘Strong Buy’ Stocks You Should Be Loading Up On Now

7 A-Rated Stocks for Your August Buy List

3 Biotech Stocks to Buy Before Drug Trials End

3 Long-Term Stocks You Better Be Buying on Each and Every Dip

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Novo Nordisk A/S ADR (NVO)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

NVO Stock Predictions, Articles, and Novo Nordisk A/S ADR News

Subscriber Sign in